Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study

Generalized Anxiety Disorder Clinical Trial

Official title:

Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03549819
• Other study ID #: CBD_ANX
• Status: Recruiting
• Phase: Phase 3
• Start date: December 15, 2021
• Est. completion date: February 2024

Study information

• Verified date: February 2023
• Source: McMaster University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This proposed study aims to evaluate the efficacy of daily Cannabidiol (CBD) Oil Capsules in treating symptoms of DSM-5 anxiety disorders, using a two-arm, 8-week randomized, placebo-controlled trial in adults aged 21-65 years. The study will also evaluate the relationship between inflammation, anxiety and CBD using biological markers as well as examine the neuro-cognitive effects of CBD treatment.

Description:

The study will be a randomized, double-blind, placebo-controlled parallel design comparing the efficacy and safety of flexibly dosed CBD Oil capsules versus placebo for the treatment of adults, aged 21 to 65 years with a primary Diagnostic and Statistical Manual 5 (DSM-5) anxiety disorder: Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Panic Disorder (PD), or agoraphobia. A total 50 participants (n=25/cell) who meet the inclusion criteria will be randomized to receive 1 of 2 treatments in a 1:1 ratio: CBD Oil Capsules or matching placebo, with the possibility of dose titration during this 8-week period. The outcomes of this research will make a significant contribution to enhance our current understanding of the effects of cannabis in anxiety disorders. To be involved in this study, the study doctor will first check that the participant is qualified. This is called screening, and will involve a clinical assessment, physical exam and urine tests. This visit may take up to 3 hours to complete. If the participant successfully completes screening the participant will start treatment in one of the two assigned treatment groups. Treatment is 8 weeks. Participants will come to the study clinic 6 times during the treatment phase of the study. Each visit will last 1 to 2 hours. Each visit will involve reporting any side effects that the participant may have experienced, completing questionnaires about mood and anxiety symptoms, sleep, overall functioning and alcohol and drug use. Participants will also be assessed by the study doctor. The first and last visits will also involve blood work and completing a number of tasks on the computer, which measure focus, attention and memory. Each participant will be involved in the study for a maximum of 10 weeks. This includes the screening visit and follow-up visit.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: February 2024
• Est. primary completion date: December 15, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male or female outpatients 21-65 years of age with a primary psychiatric diagnosis of either GAD, SAD, PD or agoraphobia as defined by DSM-5 criteria and a HAM-A score of = 22.

2. Physical exam and laboratory findings without clinically significant abnormalities.

3. Participants must agree to abstain from recreational cannabis use for the duration of the study.

4. Concomitant psychotropic medication use will be allowed provided that the dose has been stable for 8 weeks prior to randomization. (including antidepressants, anti-psychotics, anti-convulsants, benzodiazepines, stimulants, mood stabilizers)

5. The ability to comprehend and satisfactorily comply with protocol requirements.

6. Written informed consent given prior to entering the baseline period of the study.

Exclusion Criteria:

1. Current recreational or medicinal use of cannabis within 4 weeks of study initiation.

2. Participants with a lifetime history of cannabis use disorder or other substance use disorders (except tobacco use disorder)will be excluded.

3. Participants with a lifetime history of daily cannabis use will be excluded.

4. Dose changes of concomitant medication will not be permitted during the study period.

5. Pregnant women, lactating women, and women of childbearing potential who are not using medically accepted forms of contraception (e.g., IUD, oral contraceptives, barrier devices, condoms and foam, or implanted progesterone rods stabilized for at least 3 months), or women who are planning on becoming pregnant.

6. Diagnosis of any of the following mental disorders as defined by the DSM-5: a lifetime history of schizophrenia or any other psychosis, mental retardation, organic medical disorders, bipolar disorder. Entry of patients with obsessive compulsive disorder or posttraumatic stress disorder will be permitted if the anxiety disorder is judged to be the predominant disorder, in order to increase accrual of a clinically relevant sample.

7. Major depression will be allowed if not severe (Montgomery Asberg Depression Rating Scale-MADRS = 25). Patients with significant suicidal ideation (MADRS item 10 score > 3) or who have enacted suicidal behaviours within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.

8. Participants with a family history of psychosis will be excluded.

9. Participants who have a history of adverse reactions to cannabis will be excluded.

Related Conditions & MeSH terms

• Agoraphobia
• Anxiety Disorders
• Disease
• Generalized Anxiety Disorder
• Panic Disorder
• Phobia, Social
• Social Anxiety Disorder

Intervention

Drug:
• Cannabidiol (CBD) Oil Capsules
200 mg CBD- titrated as tolerated up to a maximum 2 capsules twice daily (200 mg- 800 mg total dose) Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)
• Sunflower Lecithin Oil in Capsule
Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)

Locations

Country	Name	City	State
Canada	MacAnxiety Research Centre	Hamilton	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
McMaster University	Tilray

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hamilton Anxiety Rating Scale (HAM-A)	The 14-item HAM-A was developed to assess general anxiety symptoms in a clinical population and has proven sensitive to change with treatment. It is a clinician-rated measure and will be administered at each visit by a trained, blinded rater, using the Structured Interview Guide for the HAM-A. It has 14-items to rate the intensity of psychic and somatic anxiety on a 5-point severity scale. Each item ranging from 0 (not present) to 4 (very severe) are summed up to give a total possible score of 0 (not present) to 56 (very severe), where lower scores indicates less anxiety.	Change from baseline to week 8
Secondary	Clinical Global Impression - Severity (CGI-S)	The CGI-S is a clinician-rated instrument used to assess global severity of symptoms. The CGI-S ranges from 1 (normal, not ill) to 7 (among the most severely ill).	Change from baseline to week 8
Secondary	Clinical Global Impression - Improvement (CGI-I)	The CGI-I is a clinician-rated instrument used to assess overall improvement of illness. The CGI-I ranges from 1 (very much improved) to 7 (very much worse).	Change from baseline to week 8
Secondary	Generalized Anxiety Disorder-7 (GAD-7)	The GAD-7 is a self-reported questionnaire that measures the severity of various signs of GAD. It contains seven items with a 4-point scale (range: 0 to 3). The total possible score is ranged from 0 to 21, with higher scores representing greater severity of GAD.	Change from baseline to week 8
Secondary	Liebowitz Social Anxiety Scale- Self Report (LSAS-SR)	The LSAS-SR is a 24 item scale that provides separate scores for fear and avoidance in social and performance situations with higher scores representing increased social anxiety. The LSAS-SR contains three total scores 1) total fear score (0-72), 2) total avoidance score (0-72) and total overall score (0-144).	Change from baseline to week 8
Secondary	Panic and Agoraphobia Scale (PAS)	The PAS is a measure of the severity of illness in patients with panic disorder (with or without agoraphobia). It has 13 items with a 5-point scale (range: 0-4). The total possible score is ranged from 0 to 52, with higher scores representing increased severity of illness. It contains 5 sub-scales: panic attacks, agoraphobic avoidance, anticipatory anxiety, disability, and functional avoidance (health concerns).	Change from baseline to week 8
Secondary	Quick Inventory of Depressive Symptomology (QIDS)	The QIDS is a self-report measure of depression. It contains 16 items with a 4-point scale (range: 0 to 3) which assess the severity of the nine diagnostic symptom criteria used in the DSM: Sleep disturbance, sad mood, decrease/increase in appetite/weight, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, and psychomotor agitation/retardation. The total possible score is ranged from 0 to 27, with higher scores representing greater severity of depression.	Change from baseline to week 8
Secondary	Sheehan Disability Scale (SDS)	The SDS is a 3 question instrument designed to assess functional impairment associated with mental disorders in three domains: work impairment, social impairment, and impairment of family life or home responsibilities. Each sub-scale score ranges from 0 to 10 and a total disability score, calculated as the sum of scores for each question ranges from 0 to 30. Higher scores reflect greater impairment.	Change from baseline to week 8
Secondary	World Health Organization Disability Assessment Scale (WHODAS 2.0)	The WHODAS 2.0 is a 36-item self-administered questionnaire that covers 6 domains of functioning, including: Cognition, mobility, self-care, getting along with people, life activities, participation. Each question ranges from 'none' to 'extreme or cannot do'. The scores assigned to each of the items - "none" (0), "mild" (1) "moderate" (2), "severe" (3) and "extreme" (4) - are summed to give a total score that ranges from 0 to 144, with higher scores representing a greater degree of functional limitation.	Change from baseline to week 8
Secondary	Insomnia Severity Index (ISI)	The ISI has 7 questions with a 5-point score (range: 0 to 4). The total possible score is ranged from 0 to 28, with higher scores reflecting greater severity of sleep difficulty.	Change from baseline to week 8
Secondary	Marijuana Craving Questionnaire	The Marijuana Craving Questionnaire is a 47-item self-report instrument that assesses marijuana craving along four dimensions: compulsivity, emotionality, expectancy, and purposefulness. Each item is answered with a 7-point scale from 1 (strongly disagree) to 7 (strongly agree).	Change from baseline to week 8
Secondary	Obsessive Compulsive Inventory-Revised (OCI-R)	The OCI-R is a self-report scale for assessing symptoms of Obsessive-Compulsive Disorder (OCD). It consists of 18 questions with a 5-point scale (range: 0 to 4). The possible range of scores is 0 to 72, with higher scores indicating a greater likelihood of the presence of OCD.	Change from baseline to week 8
Secondary	PTSD Checklist (PCL-5)	The PCL-5 is a 20 item self-report measure that assesses symptoms of PTSD. Each item is rated on a 5-point scale from 0 (not at all) to 4 (extremely). The possible range of scores is 0 to 80, with higher scores indicating greater severity of PTSD.	Change from baseline to week 8
Secondary	Drug Effects Questionnaire (DEQ)	The DEQ assesses the extent to which participants 1) feel any substance effect(s), 2) feel high, 3) like the effects, 4) dislike the effects, and 5) want more of the substance using 100mm Visual Analog Scales.	Change from baseline to week 8
Secondary	Marijuana Withdrawal Checklist	The Marijuana Withdrawal Checklist has 22 items that assess mood, behavioural, and physical symptoms associated with marijuana withdrawal. Each item is rated on a 4-point scale from 0 (none) to 3 (severe). A total score is obtained by summing each of the item totals (range 0 to 66). Higher scores indicated more severe symptoms associated with marijuana withdrawal.	Change from baseline to week 8
Secondary	Shipley II: Verbal	Measures verbal intelligence quotient (IQ) - crystallized intelligence	Baseline
Secondary	Shipley II: Abstraction	Measures abstract intelligence quotient (IQ) - fluid intelligence	Baseline
Secondary	Digits Forward Test	Measures attention	Change from baseline to week 8
Secondary	Digits Backward Test	Measures working memory	Change from baseline to week 8
Secondary	Go/No-Go Test	Measures behavioural inhibition	Change from baseline to week 8
Secondary	Monetary Choice Questionnaire	Measures impulsive decision making	Change from baseline to week 8
Secondary	Probabilistic Choice Questionnaire	Measures risky decision making	Change from baseline to week 8
Secondary	Trails A and B Task	Measures visual attention and switching	Change from baseline to week 8
Secondary	Rey Auditory Verbal Learning Test	Measures short-term auditory-verbal memory	Change from baseline to week 8
Secondary	Simple Visual Reaction Time Task	Measures reaction time	Change from baseline to week 8
Secondary	Sustained Attention to Response Task	Measures sustained attention	Change from baseline to week 8
Secondary	Experimental Drug Purchase Task	Measures drug abuse liability	Week 8
Secondary	Inflammatory Markers	Serum levels of IL-1ß, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, TNF-a and IFN-?	Change from baseline to week 8